Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in these patients and, thereby, provide evidence in support of the role of cannabis as a \"self-medication\" agent for them.
Epistemonikos ID: 5bb362605c13823e920052704d8bc81aa6a0397e
First added on: Apr 23, 2019